Experimental Oncology
  • Home
    • About edition
  • New issue
  • Archive
  • Author
  • Information for authors
  • Publications requirements
  • Actual information
  • Book review
  • Brief report
  • Case reports
  • Clinical experience
  • Digest
  • Editorial
  • Exchange of experience
  • Experimental research
  • History of oncology
  • Information
  • International experience
  • Lectures
  • Materials of scientific conferences
  • Official information
  • Opinion
  • Original investigations
  • Review
  • Supplements

    Ключевое слово :   doxorubicin

    THE COMBINATION OF LASER IRRADIATION AND DOXORUBICIN AS A FACTOR OF TUMOR CELL APOPTOSIS INDUCTION
    THE COMBINATION OF LASER IRRADIATION AND DOXORUBICIN AS A FACTOR OF TUMOR CELL APOPTOSIS INDUCTION
    Authors:Konovalenko S.V. Zadvornyy T.V. №24 3 2022 7
    DETERMINATION OF EFFECTS AND OPTIMIZATION OF PHOTOBIOMODULATION AND PHOTODYNAMIC THERAPY PARAMETERS FOR PROSTATE AND BREAST CANCER CELL LINES OF DIFFERENT MALIGNANCY GRADE
    DETERMINATION OF EFFECTS AND OPTIMIZATION OF PHOTOBIOMODULATION AND PHOTODYNAMIC THERAPY PARAMETERS FOR PROSTATE AND BREAST CANCER CELL LINES OF DIFFERENT MALIGNANCY GRADE
    Authors:Lykhova O.O. Konovalenko S.V. Chepurna O.M. №23 4 2021 24
    PRECLINICAL INVESTIGATION OF THE INFLUENCE OF B. SUBTILIS IMV B-7724 LECTIN ON THE DYNAMICS OF MACROPHAGES FUNCTIONAL ACTIVITY AFTER TRANSPLANTATION OF CHEMOSENSITIVE OR CHEMORESISTANT EXPERIMENTAL TUMORS
    PRECLINICAL INVESTIGATION OF THE INFLUENCE OF B. SUBTILIS IMV B-7724 LECTIN ON THE DYNAMICS OF MACROPHAGES FUNCTIONAL ACTIVITY AFTER TRANSPLANTATION OF CHEMOSENSITIVE OR CHEMORESISTANT EXPERIMENTAL TUMORS
    Authors:Chumak A.V. Fedosova N.І. Cheremshenko N.L. Karaman О.М. ... №23 1-2 2021 17
    USE OF MACHANOCHEMICALLY ACTIVATED CHARGED NANOPARTICLES OF DOXORUBICIN AS A FACTOR LIMITING COMPLICATIONS IN POLYCHEMOTHERAPY OF PATIENTS WITH MALIGNANT LYMPHOMAS
    USE OF MACHANOCHEMICALLY ACTIVATED CHARGED NANOPARTICLES OF DOXORUBICIN AS A FACTOR LIMITING COMPLICATIONS IN POLYCHEMOTHERAPY OF PATIENTS WITH MALIGNANT LYMPHOMAS
    Authors:S.A. Sivkovich V.E Orel N.N. Dzyatkovskaya 2019-05-07 4
    APPLYING OF LIPOSOMAL FORM OF DOXORUBICIN IN PATIENTS WITH DOXORUBICIN-RESISTANT BREAST CANCER
    APPLYING OF LIPOSOMAL FORM OF DOXORUBICIN IN PATIENTS WITH DOXORUBICIN-RESISTANT BREAST CANCER
    Authors:Pivnuk V.M. Tymovska Yu.O. Ponomareva O.V. Kulyk G.I. ... №9 2 2007 1
    USE OF MACHANOCHEMICALLY ACTIVATED CHARGED NANOPARTICLES OF DOXORUBICIN AS A FACTOR LIMITING COMPLICATIONS IN POLYCHEMOTHERAPY OF PATIENTS WITH MALIGNANT LYMPHOMAS
    USE OF MACHANOCHEMICALLY ACTIVATED CHARGED NANOPARTICLES OF DOXORUBICIN AS A FACTOR LIMITING COMPLICATIONS IN POLYCHEMOTHERAPY OF PATIENTS WITH MALIGNANT LYMPHOMAS
    Authors:Sivkovich S.A. Orel V.E Dzyatkovskaya N.N. №9 3 2007 No views
    TREATMENT OF CHILDREN WITH OSTEOSARCOMA
    TREATMENT OF CHILDREN WITH OSTEOSARCOMA
    Authors:Kobys V.L. Klymnyuk G.I. Tarasova T.O. Ryepina N.V. ... №8 4 2006 1
    Читаються за рейтингом

    REPLICATIVE STRESS PROTEINS AS POTENTIAL PROGNOSTIC MARKERS OF RECURRENCE...

    MARKERS OF BONE TISSUE REMODELING IN CARCINOGENESIS, TUMOR PROGRESSION AND...

    IMMUNOPHENOTYPIC PROFILE OF MALIGNANT B-LYMPHOCYTES OF PATIENTS WITH...

    THE INFLUENCE OF SPERMINE ON THE SURVIVAL AND ELECTROKINETIC CHARACTERISTICS...

    CURRENT STATE OF LABORATORY DIAGNOSIS OF MATURE B-CELL...

    Publisher MORION Apteka online Компендиум — справочник лекарств №1 Chasopys online Oncology

    «Morion» publishing house
    Editorial office and publisher: 02140, Kyiv, ave. Bazhana 10A
    Tel.: +380 (44) 585-97-10

    Specialized medical online edition for doctors,
    pharmacists, students of medical and pharmaceutical universities
    pharmaceutical universities. Disclaimer

    Publisher MORION Apteka online Компендиум Chasopys online Oncology